Compare AbbVie Inc (ABBV) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs BigBearai Holdings Inc — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while BigBearai Holdings Inc trades at $3.31 (market cap $1.64B). The key difference: AbbVie Inc is far larger — about 274.3× BigBearai Holdings Inc's market cap, and AbbVie Inc pays a 2.72% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| ABBV | BBAI | |
|---|---|---|
Market Cap | $449.91B | $1.64B |
Sector | Health | Technology |
52-Week High | $261.07 | $8.91 |
52-Week Low | $184.85 | $3.05 |
Enterprise Value | $513.38B | $1.32B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
BBAI trades at $3.58, up 1.42% today, but technical indicators signal a bearish trend with strong selling pressure. The company reported a net loss of $293.91 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights expansion into AI-powered airport security and government contracts, though high SG&A expenses and persistent losses remain concerns. Analyst consensus is cautious, with 75% hold ratings.
The outlook is challenged by ongoing losses and rich valuation, but growth in AI contracts and backlog offers potential upside. Key risks include execution on profitability, competitive pressures, and reliance on government spending. Investors should weigh the high-risk, high-reward profile amid volatile market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
